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Abstract
Background: Chronic tinnitus is a frequent condition, which can have enormous impact on patient's life and which is
very difficult to treat. Accumulating data indicate that chronic tinnitus is related to dysfunctional neuronal activity in the
central nervous system. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive method which allows to
focally modulate neuronal activity. An increasing amount of studies demonstrate reduction of tinnitus after repeated
sessions of low-frequency rTMS and indicate that rTMS might represent a new promising approach for the treatment of
tinnitus. However available studies have been mono-centric and are characterized by small sample sizes. Therefore, this
multi-center trial will test the efficacy of rTMS treatment in a large sample of chronic tinnitus patients.
Methods/Design: This is a randomized, placebo-controlled, double-blind multi-center trial of two weeks 1 Hz rTMS-
treatment in chronic tinnitus patients. Eligible patients will be randomized to either 2 weeks real or sham rTMS
treatment. Main eligibility criteria: male or female individuals aged 18–70 years with chronic tinnitus (duration > 6
months), tinnitus-handicap-inventory-score ≥ 38, age-adjusted normal sensorineural hearing (i.e. not more than 5 dB
below the 10% percentile of the appropriate age and gender group (DIN EN ISO 7029), conductive hearing loss ≤ 15dB.
The primary endpoint is a change of tinnitus severity according to the tinnitus questionnaire of Goebel and Hiller
(baseline vs. end of treatment period). A total of 138 patients are needed to detect a clinical relevant change of tinnitus
severity (i.e. 5 points on the questionnaire of Goebel and Hiller; alpha = 0.05; 1-beta = 0.80). Assuming a drop-out rate
of less than 5% until the primary endpoint, 150 patients have to be randomized to guarantee the target number of 138
evaluable patients. The study will be conducted by otorhinolaryngologists and psychiatrists of 7 university hospitals and
1 municipal hospital in Germany.
Discussion: This study will provide important information about the efficacy of rTMS in the treatment of chronic
tinnitus.
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Background
Subjective tinnitus is a frequent auditory sensation experi-
enced in the absence of an external or internal acoustic
stimulus. Tinnitus may present only sporadically or may
manifest as constant ear-ringing of high intensity that
entrains significant morbidity and may progress to a
chronic debilitating condition. There is increasing evi-
dence from electrophysiological and functional neuroim-
aging studies that tinnitus results from increased neuronal
activity within the central auditory pathways [1]. Similar
like in auditory hallucinations [2] the increased neuronal
firing in the auditory cortex results in the perception of a
phantom sound. This notion is supported by recent neu-
roimaging studies which point to a pathologically over
activated, distributed cortical network involving the infe-
rior colliculus [3], the thalamus [4], and the primary audi-
tory cortex [4-7] in subjects with tinnitus. The
pathophysiological relevance of this network has been
demonstrated recently by transient suppression of tinni-
tus after high-frequency rTMS to the temporal and tem-
poro-parietal cortex [8,9].
Low-frequency rTMS (1 Hz) is known to reduce neural
activity in directly stimulated brain regions [10,11] as well
as in structurally connected remote brain regions [11,12].
For these reasons low-frequency rTMS has been proposed
as an innovative and causally orientated treatment strat-
egy for pathological conditions with increased cortical
activity [13]. Consequently, applied to the left temporo-
parietal cortex rTMS has been repeatedly demonstrated to
reduce auditory hallucinations in patients with schizo-
phrenia [14].
In pilot studies, first evidence for a beneficial effect of
magnetic resonance imaging (MRI) and positron emis-
sion tomography (PET) guided neuronavigated low-fre-
quency rTMS has been found in patients with chronic
tinnitus [15]. This finding has been confirmed by several
controlled trials which all demonstrated a significant
reduction of tinnitus severity after five to ten days of active
rTMS as compared to sham stimulation [16-18]. Neuro-
physiological work could recently detect that rTMS-
induced improvement in tinnitus complaints was paral-
leled by changes in cortical excitability, suggesting, that
this beneficial therapeutic effect is associated with the
induction of neuroplastic processes [19]. In line with
these data, neuroimaging studies using voxel-based mor-
phometry (VBM) demonstrated that low-frequency rTMS
over auditory brain regions is able to induce profound
changes in gray matter both in cortical auditory brain
areas as well as in the thalamus [12]. Since neuroplastic
alterations at the level of the thalamus seem to be essen-
tial in the generation of chronic tinnitus [20], low-fre-
quency rTMS may represent a new approach for treating
this disorder by inducing neuroplasticity in selective corti-
cal networks closely linked to its pathogenesis. The use of
rTMS in chronic tinnitus is further supported by studies
showing that rTMS has beneficial effects in a variety of
neuropsychiatric disorders associated with focal hyperex-
citability such as focal dystonias, focal epilepsy and post-
traumatic stress disorder [11,21,22].
Taken together, a multitude of studies indicate a potential
of low-frequency rTMS for the treatment of auditory
phantom perceptions. With regard to chronic tinnitus,
especially imaging guided rTMS has been proven to be
beneficial in the treatment of chronic tinnitus. Since neu-
ronavigated rTMS is sophisticated, costly and time con-
suming this kind of application is strongly limited and
not applicable in routine activity. Due to these considera-
tions, a simple and reliable method for stimulating the
auditory cortex based on the 10–20 EEG system has been
recently developed [23] and will be used in the present
trial. Furthermore, studies so far investigated only rela-
tively small populations. Therefore, in order to render
rTMS as an effective treatment according to the principle
of evidence based medicine, it is necessary to assess the
efficacy of this treatment in a properly designed and con-
ducted randomized-controlled trial in a large patient sam-
ple.
Methods
Design of the trial
This is a multicenter, randomized, patient and observer-
blind, sham-controlled, parallel-group study of 2 weeks 1
Hz rTMS treatment plus 24 weeks follow-up in patients
with moderate to severe chronic tinnitus. Eligible patients
will be randomly assigned to either 2 weeks real rTMS
treatment or sham treatment (figure 1).
Study population
Female and male subjects aged 18 to 70 years are eligible
for study participation if they meet the following criteria:
Inclusion criteria
￿ Written informed consent
￿ Diagnosis of chronic tinnitus
￿ Patient has a score of ≥ 38 on the Tinnitus Handicap
Inventory (assessed during routine clinical diagnostics in
the last 12 weeks before start of treatment)
￿ Tinnitus duration of more than 6 months
￿ Age-adjusted normal sensorineural hearing determined
by an audiogram within the last 12 weeks before start of
treatment, i.e. no more than 5 dB below the 10 % percen-
tile (DIN EN ISO 7029) of the appropriate age and gender
group in all measured standard frequencies. Furthermore,BMC Psychiatry 2008, 8:23 http://www.biomedcentral.com/1471-244X/8/23
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no conductive hearing loss of more than 15 dB in neither
of the measured standard frequencies.
￿ naïve regarding rTMS
Exclusion criteria
￿ Objective Tinnitus
￿ Other forms of tinnitus treatments at the same time
￿ Clinically relevant psychiatric co-morbidity as judged by
an experienced psychiatrist, especially diagnose groups
F1-3 according to the International Classification of dis-
eases (ICD-10)
￿ Concomitant treatment with psychotropic drugs
￿ History or evidence of significant brain malformation or
neoplasm, head injury, cerebral vascular events, neurode-
generative disorder affecting the brain or prior brain sur-
gery
￿ Severe unstable somatic co-morbidity
￿ Cardiac pace makers, other electronic implants, intracra-
nial metallic particles
￿ History of seizures or epileptic activity
￿ Pregnancy and lactation
￿ Women in child-bearing-age without contraception
￿ Patients who cannot communicate reliably with the
investigator or who are not likely to cope with the require-
ments of the trial
￿ Participation in a clinical trial within the last 30 days
before start of this clinical trial
Participating centers
This study will be conducted by otorhinolaryngologists
and psychiatrists with wide experience in the treatment of
patients with chronic tinnitus from seven university hos-
pitals and one municipal hospital all over Germany. All
participating centers have experience in conducting rTMS-
treatment studies.
Study treatments
Screening is performed during the routine clinical tinni-
tus-consultations, and no additional study specific inves-
tigations are necessary to determine eligibility. After
screening, written informed consent, baseline assess-
ments, and randomization, patients will be treated with
either real or sham low-frequency rTMS over a period of 2
weeks. rTMS will be administered according to current
safety guidelines [24]. Magstim Super Rapid (The Mag-
stim Company Ltd, Whitland, UK) or Medtronic MagPro
(Medtronic GmbH & Co. KG, Düsseldorf, Germany) stim-
ulators will be used for stimulation as available in the par-
ticipating centers. Figure-of-eight-coils will be used for
real stimulation. Sham stimulation will be carried out by
tilting the coil 45° away from the skull with one wing
touching the skull. The stimulation parameters have been
chosen according to successful pilot studies [15,25] and
modified with respect to duration, coil positioning and
control condition. Recent data point to a dose-response
relationship of rTMS treatment in a variety of neuropsy-
chiatric diseases as well as in tinnitus treatment [23,26].
Furthermore, coil positioning using the 10–20 EEG-sys-
tem has been proven to guarantee exact placement of the
TMS coil over the auditory cortex without the need of
using MR- and PET-guidance. Finally, finding an adequate
placebo condition [27] is still under debate in clinical
rTMS studies [28]. Here, sham stimulation will be per-
formed by distortion of the magnetic coil 45° away from
the skull with one wing touching the skull. In contrast to
sham coils, this kind of sham stimulation does not induce
a sufficiently strong magnetic field in the brain tissue to
evoke any biological response but is still eliciting some
kind of skull sensation. Especially in the context of tinni-
tus treatment studies, controlling for somatosensory stim-
ulation seems to be critical since somatosensory input is
able to modulate tinnitus sensation [1].
After screening, written informed consent, and baseline
assessments, patients will be randomized to one of two
parallel groups with the following stimulation parame-
ters:
Treatment group will receive real stimulation: 2 × 5 ses-
sions, 1 Hz rTMS, stimulation intensity 110% related to
the individual resting motor threshold, 2000 stimuli per
session, coil position 10–20 guided over left primary
auditory cortex.
Control group will receive sham stimulation by distor-
tion of the magnetic coil 45° away from the skull with one
Trial design Figure 1
Trial design.
Randomization (N=150)  
Group A  Group B 
Sham rTMS treatment  Real rTMS treatment 
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wing touching the skull. Coil positioning and stimulation
parameters as in the treatment group.
At the beginning of the first treatment session, the individ-
ual resting motor threshold for the right abductor pollicis
brevis muscle of each participant will be determined
according to [29].
Blinding
As already mentioned, blinding constitutes a substantial
methodological challenge in rTMS studies. Therefore, a
blinded design will be applied, in which patients and clin-
ical raters will be blind to treatment conditions (observer
blind). rTMS treatment will be provided by the non-
blinded study staff. Patients have to be naïve regarding
rTMS treatment and will not be informed about technical
details of rTMS application. As the non-blinded study staff
applying rTMS treatment needs to know whether real or
sham rTMS is to be applied, and automatic rTMS is meth-
odologically not feasible in clinical settings to date, the
non-blinded study staff applying rTMS will be instructed
not to communicate the treatment arm to anybody
involved in patient management, in order to prevent any
impact on blinding. The investigators performing all other
assessments will be experienced physicians, not involved
in rTMS treatment of the patient, and will perform all
study specific procedures, e.g. getting informed consent,
handing out clinical questionnaires or discussing any
details about the conduct of the study with the patients.
To assess successful blinding of the trial, each patient will
be asked at the final visit (V14, day 181) whether or not
he or she guesses to have been treated with real or sham
rTMS.
Objectives
General objective
Aim of this trial is to evaluate the efficacy of low-frequency
rTMS in the treatment of chronic tinnitus. Based on the
findings in pilot studies we hypothesize that two weeks
treatment of low-frequency rTMS is more efficient in alle-
viating symptoms of chronic tinnitus and improving sec-
ondary symptoms like quality of life, cognitive
functioning or depressive symptoms than sham treat-
ment.
Primary objective
To evaluate the efficacy of real rTMS versus sham rTMS in
the treatment of chronic tinnitus by means of a change of
tinnitus severity according to the tinnitus questionnaire of
Goebel & Hiller ([30], a self-rating questionnaire; baseline
versus day 12).
Secondary objectives
To evaluate the efficacy of real rTMS versus sham rTMS
- in reducing tinnitus severity according to the tinnitus
questionnaire of Goebel & Hiller and Tinnitus Handicap
Inventory (THI; a self-rating questionnaire; [31]) during
the follow-up period (screening versus baseline versus
days 5, 12, 18, and weeks 10 and 26),
- in changes of quality of life of patients as measured by
the SF 12 (a self-rating questionnaire [32]; baseline versus
days 5, 12, 18, and weeks 10 and 26),
- in changes of depressive symptoms as measured by the
Beck Depression Inventory (BDI; a self-rating question-
naire; [33]; baseline versus days 5, 12, 18, and weeks 10
and 26),
- in changes of psychometric parameters of tinnitus (tin-
nitus minimal masking level and tinnitus loudness) as
assessed by audiological evaluation (screening versus day
18),
- in changes of structural and functional neuroplastic
adaption processes as detected by voxel-based morphom-
etry (VBM) and paired-pulse TMS (baseline versus day
12).
Adjunctive measures
Further important factors that may influence treatment
outcome may be clinical characteristics [34], the individ-
ual psychic resilience and personality traits. These will be
assessed by using the German versions of the Tinnitus
Sample Case History Questionnaire [[35]; please see also
the URL in the Availability and requirments section , the
NEO-FFI (a validated self-report questionnaire for meas-
urement of the Five Factor model basic personality traits,
neuroticism, extraversion, openness to experience, agreea-
bleness, and conscientiousness; [36]) and the RS-11 (a
patient self-rating to determine psychic resilience [37]).
Enhancing quality of outcome measures
Tinnitus is a subjective sensation that cannot be measured
by any objective parameter. Therefore, validated self rat-
ing scales (Tinnitus Handycap Inventory (THI) [31] and
Tinnitus Questionnaire of Goebel and Hiller (TQ) [30])
are the only instruments to assess changes in tinnitus
symptoms. Furthermore, tinnitus symptoms are often
fluctuating and are influenced by attention. To minimize
biases by spontaneous fluctuations or interactions with
the trial staff, the rating scales will be handed out to the
patient at the beginning of each visit before  any other
action will be taken. The patient should be seated in a
quiet, comfortable room without any disturbances while
answering the questionnaires. Furthermore, to increase
the stability of the baseline measurement, tinnitus specific
assessments (THI and TQ) will be performed three times
(at the baseline visit and two times during the baselineBMC Psychiatry 2008, 8:23 http://www.biomedcentral.com/1471-244X/8/23
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week before the first treatment session), and the average
over three measurements will be used as baseline value.
Determination of sample size
Based upon our clinical experience, a difference of 5
points in tinnitus score (range: 0 – 80) according to the
TQ is both clinically relevant and observable in a study
setting [34], and 0.486 is a conservative estimate of the
effect size [15,23,25,34]. Requiring a power (1-β) of 0.80
for detection of such an effect with a two-sided unpaired
t-test (at a level of α = 0.05) leads to a sample size of 68
per arm (active vs. sham). A simulation study was con-
ducted based on the pilot data, to study possible implica-
tions of incorporating center effects and baseline levels in
the analysis, in which it was confirmed that the planned
analysis of covariance indeed provided a power of about
0.80, given a sample size of 136. To account for the possi-
bility of a substantially larger effect size, a scheduled
interim-analysis will be carried out at the 50% recruit-
ment level, so that a 138 subjects are needed in total (see
e.g. [38]). Assuming that less than 5 percent of patients
will fail to provide post-baseline data, 150 patients will be
randomized to make sure that the target number of 138
evaluable patients will be reached.
Randomization
Before the trial starts, randomization lists will be gener-
ated by the Clinical Trials Center, University Medical
Center Freiburg, with a 1:1 treatment ratio, stratified by
study center and with randomly varying block sizes. At
each center, local investigators will have to confirm eligi-
bility of enrolled patients and the non-blinded study staff
will forward their request for randomization by fax to the
randomization center, located at the department of the
lead investigator. There, the randomization lists will be
securely stored with none of the clinical staff involved in
the trial having access to it. The randomization center will
send the allocated treatment by fax to the local non-
blinded staff performing rTMS. In addition, a standard
email including a statement that the patient has been suc-
cessfully randomized, will be send to both, the blinded
and non-blinded study staff of the center as well as to the
monitor.
Statistical Analysis
The primary endpoint for evaluation of efficacy of rTMS
for tinnitus is the change from baseline to day 12 in the
tinnitus score (TQ total score). The treatment effect will be
estimated on an intention-to-treat basis including all
patients with post-baseline data (carrying forward day 5
measurements if day 12 is missing), in an analysis of cov-
ariance including treatment and average baseline score as
fixed factors and center as a random factor. Interim analy-
sis for TQ change at day 12 will be carried out on the first
76 randomized patients following an O'Brien and Flem-
ing type sequential design with overall two-sided signifi-
cance level 0.05 (0.0052 at interim, 0.0481 at final
analysis; [38]). If more than 5% of patients fail to provide
post-baseline data, the primary analysis will be comple-
mented by sensitivity analyses exploring potential biases
induced by patterns of missingness which will be investi-
gated by logistic regression on comprehensive baseline
information.
Secondary analyses of TQ change over time will be per-
formed in longitudinal linear mixed models based with a
pre-specified model-building strategy. For the other sec-
ondary objectives with respect to rating scales (THI, SF 12,
BDI, and CGI) a similar strategy will be employed as
applicable. For changes in cortical excitability and
changes in psychometric parameters of tinnitus assessed
by audiological examination, one-way ANOVA analysis
will be used, and for changes in brain structure voxel-
based morphometry (VBM) will be used.
Procedures
Visit schedule
An overview on the time schedule for assessing and
recording of efficacy and safety parameters is given in
table 1. Baseline assessments are followed by the two
weeks treatment period, when the patient is seen daily
from Monday to Friday (total of 10 visits). During the fol-
low-up, patients will be seen at day 18 (visit 12), day 67
(visit 13) and at the final visit at day 181. In case of treat-
ment discontinuation, efficacy parameters should be
assessed for the whole study period at all outstanding vis-
its (visits 6, 11–14, respectively). For patients who discon-
tinue the study, the premature termination visit will be
performed whenever possible.
Data collection
All randomized patients will receive a profound physical,
neuropsychological and audiological examination at the
screening and baseline visits, respectively. Beside a
detailed physical examination, vital signs (e.g. heart rate,
blood pressure, height and weight) will be determined at
visits 2, 11 and 14. Neuropsychological parameters (test
for attentional performance; TAP) will serve as a safety cri-
terion to detect any deterioration in cognitive function
and will be repeated at visit 11 (day 12) at the end of the
treatment period. Audiological examinations at screening
and visit 12 (day 18) will serve as both secondary out-
come (tinnitus masking and loudness matching) and
safety parameter (pure tone audiometry). Concomitant
medication will be documented at screening and baseline,
visit 11 at the end of the treatment period as well as at
each follow-up visit. Tinnitus-specific rating scales (THI
and TQ) will be performed three times during the baseline
week before treatment and thereafter at visits 6 and 11 –
14 together with BDI and SF-12. Moreover, informationBMC Psychiatry 2008, 8:23 http://www.biomedcentral.com/1471-244X/8/23
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on any adverse event, including side effects of study treat-
ments, will be collected during the treatment period (vis-
its 2 – 11). An independent data safety and monitor board
(DSMB) consisting of clinical and statistical experts will
critically assess adherence to the study protocol as well as
to ICH-GCP-guidelines. Together with the sponsor, the
DSMB will decide whether the trial has to be terminated
prematurely. Possible reasons encompass e.g. safety con-
cerns, unexpected high discontinuation rates or a large
effect size on TQ at day 12 determined by the interim
analysis.
Timing
The start of the study is February 2008. With a planned
number of 138 patients providing post-baseline data, a
drop out rate for the primary outcome of less than 5% and
an expected screening to inclusion ratio of 5:1, 750
patients will have to be assessed for eligibility in all 8 cent-
ers, and 150 will be allocated for trial participation. The
recruitment and treatment period will be 27 months, with
6 additional months to complete follow-up. Analyses and
reporting will be estimated to be 6 months, resulting in a
total duration of about 3 years.
Table 1: Study Plan
Screening Baseline R3 Treatment Follow-Up
Visits V0 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 final visit4
Week Week 0 Week 1 Week 2 Week 3 Week 10 Week 26/PTV
Day -  1 1  t o  - 9 1234589 1 0 1 11 2 1 7  –  1 96 6 – 6 8 1 8 0  –  1 8 2
Rating Scales (THI) X1 X2 XX X X X
Otologic 
examination and 
audiological 
assessment
X1 X
Informed Consent X
Demographic Data X
Medical History X
Documentation of 
Comorbidity
XX
Documentation of 
concomitant 
medication
XX X X X X
Physical 
examination
XX X
Vital Signs XX X X
Rating Scales 
(Goebel&Hiller, 
BDI, SF 12)
X2 XX X X X
Tinnitus-Severity XX X X X X X
NEO FFI, RS-11 X
CGI XX X X X X X
Neuropsychological 
Assessment
XX
Cortical Excitability 
(pTMS)
XX
Structural 
Neuroimaging 
(VBM)
XX
Inclusion/Exclusion X
Randomization X
rTMS Treatment XXXXXXXX X X
Documentation of 
Adverse Events
XXXXXXXX X X
1 = results of routine clinical investigations
2 = each patient receives at V1 two versions of THI and TQ to be completed on Monday and Friday before V2
3 = randomisation
4 = Visit 14 or PTV = Premature Termination VisitBMC Psychiatry 2008, 8:23 http://www.biomedcentral.com/1471-244X/8/23
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Ethical aspects
Safety of rTMS
Applied under previously published safety guidelines
[24], rTMS has been proven to be a safe and well tolerated
therapy in a broad range of studies encompassing distinct
neuropsychiatric diseases. Considerable side effects of
rTMS encompass potentially occurring physical discom-
fort on the scalp during stimulation and headache after
rTMS with an incidence of about 5%. Other relevant side
effects are not expected if known contraindications (see
exclusion criteria) are respected.
Ethics committee
The study protocol as well as the documents to obtain
patient's informed consent have been approved by the
independent ethics committee of the coordinating center
at the university of Regensburg on October 24th 2006. The
study will be performed in accordance with the ethical
principles that have their origin in the Declaration of Hel-
sinki and are consistent with the ICH guidelines for Good
Clinical Practice. The trial has been registered at the Inter-
national Standard Randomized Controlled Trial Number
Registration (ISRCTN89848288).
Patient information and informed consent
The patient will be fully informed about the nature, pur-
pose, possible risks and benefit of the study by the inves-
tigator before any study specific actions will take place.
Patients will be notified that they are free to discontinue
from the study at any time without any disadvantages for
further clinical care. There will be sufficient time to ask
questions and to consider the information provided. If the
patient is willing to participate in the trial, he or she will
be asked to sign the informed consent form. Patients must
be withdrawn from study treatment when judged neces-
sary by the investigator. Reasons may be for example
safety concerns, severe non-compliance, incorrect enrol-
ment or randomization. Follow-up will end in case of
withdrawal of the informed consent by the patient.
Data management
Data management will be performed by the Center for
Clinical Studies, University of Regensburg. An Access
database will be used and after closure of the database,
data will be transferred to the Clinical Trials Center, Uni-
versity Medical Center Freiburg for data analysis.
Monitoring
Monitoring will be performed according to current ICH-
GCP-guidelines. Each center will be initiated by a stand-
ardized conference call using a presentation describing
the basic principles of the study and most relevant proce-
dures (e.g. getting informed consent, randomization,
treatment procedures, emergency unblinding). In addi-
tion, each center will be visited regularly by the monitor
depending on the patient recruitment.
Discussion
Although chronic tinnitus is a frequent and often disa-
bling condition, no treatment can yet be considered well
established in terms of providing replicable long-term
reduction of tinnitus impact in excess of placebo effects
[39]. Therefore, new therapeutic approaches are highly
needed. Based on recent advances in the understanding of
the pathophysiology of tinnitus and based on an increas-
ing amount of promising pilot data, rTMS seems to hold
high potential as a new treatment tool. However, clinical
data on the efficacy are limited, mainly due to the small
sample sizes of available studies. Several methodological
difficulties had to be considered in the design of this trial.
First tinnitus is a purely subjective phenomenon, which is
difficult to assess. Second, only recently an expert consen-
sus for treatment outcome measurements in tinnitus
patients has been published [35]. Third the blinding con-
dition is more difficult to perform in rTMS studies than in
pharmacologic studies and fourth there is only very lim-
ited experience with multi-center placebo-controlled trials
conducted according to ICH-GCP guidelines for both the
indication tinnitus and the intervention rTMS.
Here we present a study protocol for a multi-center, pla-
cebo-controlled clinical rTMS trial conducted according to
ICH-GCP guidelines and to the above mentioned expert
consensus [35] and involving professional monitoring.
The presented study protocol takes into account all the
described methodological difficulties and demonstrates
the feasibility of a controlled multi-center rTMS trial
thereby enhancing the quality of the collected data. The
study sample is one of the largest ever investigated in TMS
studies and the largest sample of patients with chronic tin-
nitus.
Abbreviations
BDI: Beck Depression Inventory; DSMB: Data Safety Mon-
itor Board; GCP: Good Clinical Practice; ICH: Interna-
tional Conference on Harmonization; LOCF: last
observation carried forward; MR: magnet resonance tom-
ography; NEO FFI, NEO: Five Factor Inventary; RTMS:
repetitive transcranial magnetic stimulation; THI: Tinni-
tus Handicap Inventory; TQ: Tinnitus Questionnaire of
Goebel&Hiller; VBM: Voxel-based Morphometry; RS-11:
short for of the German questionnaire to assess resilience;
SF 12: Quality of life assessment scale.
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Tinnitus Sample Case History Questionnaire (German,
English, French, Italian, Spanish, Dutch, Czech, Portug-
ese):
http://www.tinnitusresearch.org/en/consensus/
consensus_en.php
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